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Background
Chronic obstructive pulmonary disease (COPD) is an
inflammatory lung disease associated with a 10-fold
increased risk of lung cancer (LC), independent of
smoking-status. Together these diseases contribute
tremendously to mortality worldwide. Based on the
notion that chronic inflammation forms a specific cancer-
promoting environment; we hypothesized that COPD and
non-COPD related lung tumors are molecularly distinct,
and that these differences may yield promising diagnostic
and therapeutic targets. Since genes that sustain high-
level DNA and RNA alterations are likely selectively
altered in tumor systems, we applied an integrative
multi-omics analysis to lung tumors from COPD and
non-COPD patients. To assess the potential clinical
application of these findings, we examined the methyla-
tion status of COPD+LC specific genes in non-malignant
airways from COPD patients w/LC.
Materials and methods
Multi-omics profiling (copy number, DNA methylation
and gene-expression) was performed on 76 tumor and
non-malignant lung tissues using genome-wide array
platforms. To identify genes/pathways which sustain high
DNA and RNA level changes in tumors, we developed an
algorithm to generate “Integrated Scores” for each gene
based on magnitude of concomitant DNA and mRNA
alterations. Integrated Scores were applied to all down-
stream analyses. COPD+LC specific genes were further
assessed at the level of DNA methylation in airways from
25 COPD patients w/ and w/out LC.
Results
Gene set and pathway enrichment analyses of genes
frequently and differentially disrupted at both DNA and
RNA levels in COPD tumors revealed enrichment of
transcription factor gene sets involved in inflammation-
related cancer, oxidative stress and smoking response;
the most significant being PITX2 -a putative methylation
biomarker in LC, previously associated with senescence
gene networks in COPD.
Pathways specifically disrupted in COPD tumors
included those involved in inflammation (atherosclerosis,
fibrosis and IL-17 signalling), DNA damage (14-3-3s
signalling) and synthesis of the methyl-donor, S-Adenosyl-
methionine (SAM) - a critical cofactor involved in DNA
and histone methylation. Five COPD+LC specific genes
were also altered at the DNA methylation level in non-
cancerous airways of COPD patients w/LC, including
putative cancer epigenetic diagnostic biomarkers
(CCNDBP1, HPGD), genes associated with oxidative
response and COPD progression (PPARGC1A) and
biosynthesis of SAM (MAT2B).
Conclusions
Genetic and epigenetic disruptions in lung tumors and
small airways of patients with COPD and LC are distinct
from those in corresponding tissues from patients
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w/COPD or LC alone. Genes altered in airways and
involved in lung tumorigenesis in COPD patients may
serve as clinically relevant markers for predicting LC or as
targets for chemoprevention therapies.
Authors’ details
1Department of Integrative Oncology, British Columbia Cancer Research
Centre, Vancouver, BC, Canada. 2Princess Margaret Cancer Centre, University
Health Network, Toronto, ON, Canada. 3Department of Surgery, Vancouver
General Hospital, Vancouver, BC, Canada. 4Departments of Computer Science
and Medical Biophysics, University of Toronto, Toronto, ON, Canada.
Published: 28 May 2014
doi:10.1186/2049-3002-2-S1-P82
Cite this article as: Vucic et al.: Lung tumors and non-malignant airways
from patients with chronic lung inflammatory disease bear distinct
genetic and epigenetic disruptions corresponding to metabolic
processes involved in senescence and methylation. Cancer & Metabolism
2014 2(Suppl 1):P82.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Vucic et al. Cancer & Metabolism 2014, 2(Suppl 1):P82
http://www.cancerandmetabolism.com/content/2/S1/P82
Page 2 of 2
